These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 32412152)

  • 1. Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors.
    Qin Y; Jian H; Tong X; Wu X; Wang F; Shao YW; Zhao X
    Mol Oncol; 2020 Aug; 14(8):1695-1704. PubMed ID: 32412152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios.
    Kobayashi IS; Viray H; Rangachari D; Kobayashi SS; Costa DB
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944068
    [No Abstract]   [Full Text] [Related]  

  • 3. Detection of EGFR exon 20 insertion mutations in non-small cell lung cancer: implications for consistent nomenclature in precision medicine.
    Park J; Lee B; Song JY; Sung M; Kwon MJ; Kim CR; Lee S; Shin YK; Choi YL
    Pathology; 2024 Aug; 56(5):653-661. PubMed ID: 38811262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors.
    Vasconcelos PENS; Gergis C; Viray H; Varkaris A; Fujii M; Rangachari D; VanderLaan PA; Kobayashi IS; Kobayashi SS; Costa DB
    JTO Clin Res Rep; 2020 Sep; 1(3):. PubMed ID: 34104899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
    Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
    Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the Clinical Characteristics and Prognosis of Advanced Non-Small Cell Lung Cancer with Exon 20 Insertions.
    Wang H; Xu Y; Lin J; Huang Y
    Cancer Control; 2024; 31():10732748241262190. PubMed ID: 38857163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors.
    Shaffer W; Kobayashi IS; Sentana-Lledo D; Sundararaman S; Lee MD; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB
    Lung Cancer; 2023 Jul; 181():107250. PubMed ID: 37196448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non-small cell lung cancer.
    Pan B; Liang J; Shi H; Rao K; Guo W; Zhan C
    Thorac Cancer; 2023 Nov; 14(33):3247-3258. PubMed ID: 37795778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer.
    Geng D; Guo Q; Huang S; Zhang H; Guo S; Li X
    Clin Transl Oncol; 2022 Feb; 24(2):379-387. PubMed ID: 34453698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
    Yasuda H; Park E; Yun CH; Sng NJ; Lucena-Araujo AR; Yeo WL; Huberman MS; Cohen DW; Nakayama S; Ishioka K; Yamaguchi N; Hanna M; Oxnard GR; Lathan CS; Moran T; Sequist LV; Chaft JE; Riely GJ; Arcila ME; Soo RA; Meyerson M; Eck MJ; Kobayashi SS; Costa DB
    Sci Transl Med; 2013 Dec; 5(216):216ra177. PubMed ID: 24353160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Clinicopathogenomic Features and Treatment Outcomes of EGFR and HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer: Single-Institution Experience.
    Lee SH; Jeong H; Kim DH; Jang SJ; Kim SW; Yoon S; Lee DH
    Cancer Res Treat; 2024 Jul; 56(3):774-784. PubMed ID: 38291744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
    Fang W; Huang Y; Hong S; Zhang Z; Wang M; Gan J; Wang W; Guo H; Wang K; Zhang L
    BMC Cancer; 2019 Jun; 19(1):595. PubMed ID: 31208370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Sa H; Shi Y; Ding C; Ma K
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7729-7742. PubMed ID: 37004599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinib.
    Kunimasa K; Nishino K; Kukita Y; Matsumoto S; Kawachi H; Kawamura T; Inoue T; Tamiya M; Honma K; Sugimoto N; Yamasaki T; Imamura F; Goto K; Kumagai T
    Cancer Genet; 2021 Aug; 256-257():57-61. PubMed ID: 33901930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling.
    Zwierenga F; Zhang L; Melcr J; Schuuring E; van Veggel BAMH; de Langen AJ; Groen HJM; Groves MR; van der Wekken AJ
    Lung Cancer; 2024 Nov; 197():107973. PubMed ID: 39374568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
    Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
    Wu JY; Yu CJ; Shih JY
    Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
    Hasegawa H; Yasuda H; Hamamoto J; Masuzawa K; Tani T; Nukaga S; Hirano T; Kobayashi K; Manabe T; Terai H; Ikemura S; Kawada I; Naoki K; Soejima K
    Lung Cancer; 2019 Jan; 127():146-152. PubMed ID: 30642543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
    Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Yang G; Yang Y; Hu J; Xu H; Zhang S; Wang Y
    Front Pharmacol; 2022; 13():984503. PubMed ID: 36425568
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.